When restricting to nonsynonymous mutations (see “Methods” for definition), we found that PBRM1 (6.25%), B2M (3.75%), and MAP3K4 (3.75%) were the most frequently mutated known cancer driver genes16 in this patient cohort. This evidence concerns the gene PBRM1 and cancer.